How did Compumedics fare in the first half of FY21?

  • January 20, 2021 06:06 PM AEDT
  • Team Kalkine
How did Compumedics fare in the first half of FY21?


  • Logistic problems have impacted the revenue pipeline of the company.
  • Compumedics continues to pursue potential sales opportunities in the US market.
Gold MTF non-AMP

Compumedics Limited (ASX:CMP) released a business update on Wednesday. The medical device company noted that H1 FY21 sales orders were around $20.3 million, up by 13% from $18 million in H1 FY20.

Source: CMP Presentation, 19 November 2020

It expects first half revenues to be around $17.1 million against $18.3 million in the same period last year. The company has attributed the potential dip in revenue to logistics delay in the Northern Hemisphere, due to COVID-19 restrictions.

Now, the company expects to ship the pending order in the early second half. Sales growth was achieved in Australia, Europe and DWL, while sales in the US were flat against the same period last year.

Source: CMP Presentation, 19 November 2020

Compumedics has not provided the full year guidance, but said 2H sales pipeline is tracking similar to last year’s 2H levels. The company is poised to declare the detailed and final first half results on 24 February 2021.

Meanwhile, the medical device company is progressing with its first MEG sale to BNI, which has been delayed due to the pandemic concerns in the US. Compumedics expects to complete the sale sometime in 2021 and is pursuing potential 2nd and 3rd sales from its current opportunities.

CMP last traded at $0.43, up by 2.4% from the previous close.



The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK